We are developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. 

Our lead program is our CardiAMP® autologous mononuclear cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF).

To learn more about the CardiAMP Heart Failure studies and see if you or someone you may know might be eligible for the CardiAMP Heart Failure II Trial please click on the trial link below.